aibio
Mergers ·
Chemomab amends domestication merger terms ahead of Scipher Medicine deal
A technical amendment sets a formula-based exchange ratio for a combined company of 10,000,000 shares. A later amendment cut that number to 5,000,000.
CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics (CMMB) news CMMB offering and merger news
Latest Chemomab Therapeutics news
- Listings
Chemomab reports 2025 results, cites FDA alignment and partner talks
The March 19, 2026 release recalls an August 2025 ADS ratio change that worked as a one-for-four reverse ADS split.
- Financings
Chemomab signs at-the-market agreement with LifeSci Capital for up to $7,258,687
The Israeli company may sell American depositary shares from time to time and is not obligated to sell any. LifeSci Capital will earn a 3.0% commission.
What Chemomab Therapeutics does
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of therapeutics for fibrotic and inflammatory diseases with high unmet needs. Its lead clinical product candidate, nebokitug, is a first-in-class humanized monoclonal antibody designed to bind and block CCL24, a soluble protein that promotes fibrosis and inflammation through the CCR3 receptor. The company is developing nebokitug for rare orphan diseases with no established disease-modifying treatments, including primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). It estimates approximately 70,000 patients with PSC in the United States, European Union and Japan, representing a more than $1 billion market opportunity, and approximately 170,000 patients with SSc in those markets, representing a more than $1.5 billion market opportunity. Chemomab has completed a Phase 2 clinical study of nebokitug in PSC, a rare obstructive and cholestatic liver disease. After an End-of-Phase 2 meeting with the FDA in December, 2024, the company and the FDA agreed on the design of a single Phase 3 pivotal PSC trial that could result in full regulatory approval.
| Product or program | What it is | Stage |
|---|---|---|
| Nebokitug | Humanized monoclonal antibody that binds and blocks CCL24, for fibrotic and inflammatory diseases | Phase 2 completed in PSC; single Phase 3 pivotal PSC trial agreed with FDA |
Chemomab Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.8 million | $11.3 million |
| Net income (loss) | -$9.0 million | -$13.9 million |
| Cash from operations | -$11.1 million | -$15.4 million |
| Cash and equivalents | $7.6 million | $6.1 million |
Questions about Chemomab Therapeutics
Has Chemomab Therapeutics raised money recently?
Our latest story on this, dated Jul 25, 2025: "Chemomab signs at-the-market agreement with LifeSci Capital for up to $7,258,687". The story links the filing or release it is based on. Read the story.
Is Chemomab Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Sep 30, 2026: "Chemomab amends domestication merger terms ahead of Scipher Medicine deal". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Chemomab Therapeutics?
Chemomab Therapeutics Ltd. trades under the ticker CMMB on NASDAQ.
Where is Chemomab Therapeutics listed?
Chemomab Therapeutics Ltd. is listed on NASDAQ.
What is the SEC CIK of Chemomab Therapeutics?
The SEC Central Index Key (CIK) for Chemomab Therapeutics Ltd. is 1534248. Its filings are on SEC EDGAR.
How many shares does Chemomab Therapeutics have outstanding?
575,381,320 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-23.
Which country or territory is Chemomab Therapeutics listed under?
Our directory records Chemomab Therapeutics Ltd. under Israel.
What does Chemomab Therapeutics do?
Our directory classifies Chemomab Therapeutics Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Chemomab Therapeutics?
The ISIN recorded for Chemomab Therapeutics Ltd. is US16385C2035.
Does aibio.space cover Chemomab Therapeutics?
aibio.space lists Chemomab Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Chemomab Therapeutics incorporated?
SEC records list its state or country of incorporation as L3.
What does Chemomab Therapeutics develop?
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of therapeutics for fibrotic and inflammatory diseases with high unmet needs. Its lead clinical product candidate, nebokitug, is a first-in-class humanized monoclonal antibody designed to bind and block CCL24, a soluble protein that promotes fibrosis and inflammation through the CCR3 receptor.
What is Nebokitug from Chemomab Therapeutics?
Nebokitug: Humanized monoclonal antibody that binds and blocks CCL24, for fibrotic and inflammatory diseases Stage: Phase 2 completed in PSC; single Phase 3 pivotal PSC trial agreed with FDA.
Is Chemomab Therapeutics profitable?
Chemomab Therapeutics Ltd. reported a net loss of $9.0 million for the fiscal year ended Dec 31, 2025, and used $11.1 million of cash in operations, per its annual report to the SEC.
How much does Chemomab Therapeutics spend on research and development?
$5.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Chemomab Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Listings
Reported a reverse stock split. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
- Financings
Reported a financing. SEC Form 6-K. Source
- Financings
Reported a financing. SEC Form 6-K. Source
Stock chart
SEC filings and registration
- SEC name
- Chemomab Therapeutics Ltd.
- CIK
- 1534248
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CMMB (Nasdaq)
- State or country of incorporation
- L3
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- KIRYAT ATIDIM, BUILDING 7, TEL AVIV
- Phone
- 972-77-331-0156
- Shares outstanding
- 575,381,320 as of 2025-12-31 (20-F filed 2026-03-23)
- Former names
- Anchiano Therapeutics Ltd.; BioCancell Ltd.
Recent filings
Listing details
- Company
- Chemomab Therapeutics Ltd.
- Ticker
- CMMB
- Listing
- NASDAQ
- Country or territory
- Israel
- Business scope
- Biotechnology
- ISIN
- US16385C2035
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction